Metronidazole in the treatment of non-specific vaginitis (NSV).

Jerve, F; Berdal, T B; Bohman, P; Smith, Carl C.; Evjen, O K; Gjønnaess, H; Gaasemyr, M; Hausken, L; Hesla, K; Hoftvedt, E

doi:10.1136/sti.60.3.171

Cited by 12 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our treament results with metronidazole are not as good as previously reported [1][2][3][4][5][6], This can be ex plained by the high number of IUCD users among our patients. Unfortunately, in a great number of studies IUCD users are cither included or the incidence of IUCD users is not reported [2][3][4][5]. Our findings emphasize the importance of stating the frequency of IUCD users in studies of BV.…”

Section: Discussioncontrasting

confidence: 45%

Comparison of Oral and Vaginal Metronidazole Therapy for Nonspecific Bacterial Vaginosis

Bistoletti¹,

Fredricsson²,

Hagström

et al. 1986

Gynecol Obstet Invest

View full text Add to dashboard Cite

A prospective, randomized, nonblind study was performed to compare the efficacy of a 7-day vaginal regimen with 500 mg metronidazole (Flagyl®) once a day and that of oral treatment with 400 mg metronidazole twice daily for 7 days in the treatment of nonspecific bacterial vaginosis. No treatment was given to the sexual partners and there was no restriction of sexual intercourse. 38 women completed the study and at follow-up after 4 weeks, women receiving vaginal therapy had a cure rate of 79% compared with 74% in the women on oral therapy. Cure rates were lower among users of an intrauterine contraceptive device (57 versus 88% among nonusers). The occurrence of lactate-producing bacteria (lacto-bacilli and aerobic streptococci) in the vagina was significantly higher in women after vaginal compared with oral therapy. Gardnerella vaginlis was isolated in 58% of the women after vaginal and in 44% of the women after oral treatment. It is concluded that vaginal application of 500 mg metronidazole daily for 7 days is equally effective as oral administration in the treatment of bacterial vaginosis.

show abstract

Section: Discussioncontrasting

confidence: 45%

Comparison of Oral and Vaginal Metronidazole Therapy for Nonspecific Bacterial Vaginosis

Bistoletti¹,

Fredricsson²,

Hagström

et al. 1986

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Studies that evaluated the efficacy of metronidazole for treatment of symptomatic BV have demonstrated resolution in 47%-90% of women at 4 weeks [22][23][24][25][26][27], with 7-day regimens generally producing higher rates of resolution, compared with single-dose treatment. For T. vaginalis infection, a single 2-g dose of metronidazole is the treatment of choice and has provided cure rates of 82%-88% [28 -31].…”

Section: Discussionmentioning

confidence: 99%

Improvement of Vaginal Health for Kenyan Women at Risk for Acquisition of Human Immunodeficiency Virus Type 1: Results of a Randomized Trial

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Their efficacy appears to be high-93% at 1 week, and 89% at 1 month. 91,92 However, the oral form may result in a higher incidence of diarrhea and colitis. The topical preparations are only minimally absorbed, reaching 2% to 5% of the mean peak serum concentration of systemic therapy, resulting in much lower toxicity.…”

Section: Treatmentmentioning

confidence: 99%

Evaluation and management of vaginitis

1998

View full text Add to dashboard Cite

V aginitis is a common medical problem in women that is associated with substantial discomfort and frequent medical visits. Roughly 5 to 10 million office visits per year are attributed to vaginitis. 1 Research in recent years has increased our understanding of the disease process and its potential sequelae and resulted in improved diagnostic and treatment modalities. 2-6 Nevertheless, adequate diagnosis and treatment of vaginitis in the office setting often is problematic for practitioners. 2,5,7-9 Moreover, the availability of over-the-counter medications for fungal vaginitis has increased the likelihood that women will come to medical attention with partially or inadequately treated infections. 10 We will focus on the common infectious causes of vaginal discharge-yeast infection, bacterial vaginosis, and trichomonas infection, emphasizing new developments in diagnosis, associated complications, and treatment of these infections.The initial evaluation of vaginal discharge requires an understanding of physiologic vaginal discharge and what differentiates it from abnormal, pathologic discharge. Substances from the vulvar, sebaceous, sweat, Bartholin's and Skene's glands, as well as exfoliated cells, cervical mucus, and secretions of the endometrial cavity and fallopian tubes constitute the normal physiologic secretions of the vagina. These secretions pool in the posterior fornix and do not adhere to the vaginal walls. 11 The pH of normal vaginal secretions in women of childbearing age is between 3.8 and 4.5. The presence of sperm, blood, amniotic fluid, or cervical mucus raises the vaginal pH. 11 The amount and fluidity of the discharge can vary over the menstrual cycle. Cervical mucus becomes more fluid around ovulation, and women frequently mistake this change in consistency for an abnormal discharge. Stress increases the rate of vaginal desquamation and thus the amount of discharge, which patients can also mistake for a pathologic discharge. 12 Women generally do not have other symptoms if their discharge is physiologic.In contrast, a pathologic discharge adheres to the vaginal walls and is often accompanied by irritation, pruritus, odor, or urinary symptoms such as dysuria or frequency. 6 The discharge can be thick to watery and frothy, and white to yellow, gray, or green. 11 Causes of an abnormal discharge include infectious causes of vaginitis such as yeast infection, bacterial vaginosis, and trichomonas infection, as well as cervicitis and sexually transmitted diseases such as gonorrhea and chlamydia infection. Noninfectious etiologies include chemical irritants such

show abstract

Metronidazole in the treatment of non-specific vaginitis (NSV).

Cited by 12 publications

References 8 publications

Comparison of Oral and Vaginal Metronidazole Therapy for Nonspecific Bacterial Vaginosis

Comparison of Oral and Vaginal Metronidazole Therapy for Nonspecific Bacterial Vaginosis

Improvement of Vaginal Health for Kenyan Women at Risk for Acquisition of Human Immunodeficiency Virus Type 1: Results of a Randomized Trial

Evaluation and management of vaginitis

Contact Info

Product

Resources

About